Caparica et al.19 found that a high ADRB2 expression may be a favorable prognostic factor in patients with HER2 + early breast cancer and evidence that a possible association with antiproliferative, antiangiogenic, and immunogenic effects of ADRB2. Yazawa et al.20 retrospectively analyzed 328 surgically-resected patients with NSCLC and found that positive ADRB2 expression was found in 29% of LUAD tissues, which markedly increased compared with in non-adenocarcinoma tissues. The gene discussed is ERBB2; the disease is breast carcinoma.